Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.
3.

Adenoviral B7-H3 therapy induces tumor specific immune responses and reduces secondary metastasis in a murine model of colon cancer.

Lupu CM, Eisenbach C, Lupu AD, Kuefner MA, Hoyler B, Stremmel W, Encke J.

Oncol Rep. 2007 Sep;18(3):745-8.

PMID:
17671729
4.

Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression.

Pützer BM, Hitt M, Muller WJ, Emtage P, Gauldie J, Graham FL.

Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10889-94.

5.

Expression of membrane anchored cytokines and B7-1 alters tumor microenvironment and induces protective antitumor immunity in a murine breast cancer model.

Bozeman EN, Cimino-Mathews A, Machiah DK, Patel JM, Krishnamoorthy A, Tien L, Shashidharamurthy R, Selvaraj P.

Vaccine. 2013 May 7;31(20):2449-56. doi: 10.1016/j.vaccine.2013.03.028. Epub 2013 Mar 28.

6.

Enhanced interleukin-2 gene transfer immunotherapy of breast cancer by coexpression of B7-1 and B7-2.

Emtage PC, Wan Y, Muller W, Graham FL, Gauldie J.

J Interferon Cytokine Res. 1998 Nov;18(11):927-37.

PMID:
9858314
7.

Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model.

Lee YS, Kim JH, Choi KJ, Choi IK, Kim H, Cho S, Cho BC, Yun CO.

Clin Cancer Res. 2006 Oct 1;12(19):5859-68.

8.
9.

Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.

Choi KJ, Kim JH, Lee YS, Kim J, Suh BS, Kim H, Cho S, Sohn JH, Kim GE, Yun CO.

Gene Ther. 2006 Jul;13(13):1010-20. Epub 2006 Mar 9.

PMID:
16525479
10.
11.
12.

Lack of correlation between rejection of tumor cells co-expressing interleukin-2 and B7.1 and vaccine efficiency.

Cayeux S, Richter G, Becker C, Beck C, Aicher A, Pezzutto A, Dörken B, Blankenstein T.

Eur J Immunol. 1997 Jul;27(7):1657-62.

PMID:
9247574
15.

Colon cancer cell vaccine prepared with replication-deficient vaccinia viruses encoding B7.1 and interleukin-2 induce antitumor response in syngeneic mice.

Sivanandham M, Shaw P, Bernik SF, Paoletti E, Wallack MK.

Cancer Immunol Immunother. 1998 Jul;46(5):261-7.

PMID:
9690454
16.

Tricistronic viral vectors co-expressing interleukin-12 (1L-12) and CD80 (B7-1) for the immunotherapy of cancer: preclinical studies in myeloma.

Wen XY, Mandelbaum S, Li ZH, Hitt M, Graham FL, Hawley TS, Hawley RG, Stewart AK.

Cancer Gene Ther. 2001 May;8(5):361-70.

17.

Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model.

Addison CL, Braciak T, Ralston R, Muller WJ, Gauldie J, Graham FL.

Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8522-6.

18.
19.

Enhancement of effector CD8+ T-cell function by tumour-associated B7-H3 and modulation of its counter-receptor triggering receptor expressed on myeloid cell-like transcript 2 at tumour sites.

Kobori H, Hashiguchi M, Piao J, Kato M, Ritprajak P, Azuma M.

Immunology. 2010 Jul;130(3):363-73. doi: 10.1111/j.1365-2567.2009.03236.x. Epub 2010 Feb 5.

20.

Comparative analysis of IFN-gamma B7.1 and antisense TGF-beta gene transfer on the tumorigenicity of a poorly immunogenic metastatic mammary carcinoma.

Wu RS, Kobie JJ, Besselsen DG, Fong TC, Mack VD, McEarchern JA, Akporiaye ET.

Cancer Immunol Immunother. 2001 Jul;50(5):229-40.

PMID:
11499806

Supplemental Content

Support Center